RSV Vaccine Biz Secures $100M For Series B Funding Round

By Jade Martinez-Pogue · September 23, 2024, 3:07 PM EDT

Biopharmaceutical company Vicebio Ltd. on Monday announced that it secured its Series B funding round after securing $100 million led by science-focused investment firm TCGX....

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Recent Articles By Jade

September 25, 2024
Cancer Detection Biz To Go Public Via $694M SPAC Merger
September 20, 2024
Cardinal Health Pays $1.12B For Integrated Oncology Network
September 18, 2024
Organon To Buy Psoriasis Treatment Biz For Up To $1.2B
September 09, 2024
MBX Biosciences Seeks Up To $136M In Upcoming IPO
September 03, 2024
Aspire Biopharma Inks SPAC Deal At $316M Valuation
September 03, 2024
Semnur Pharmaceuticals To Go Public Via $2.5B SPAC Merger
August 30, 2024
Cancer Detection Co. Valued At $375M In SPAC Merger
August 26, 2024
McKesson Inks $2.49B Deal For Cancer-Focused Biz
August 23, 2024
Covington-Led Getinge Pays $477M For Organ Transplant Biz
August 16, 2024
Avantor Sells Clinical Services Biz To PE Shop In $650M Deal